Patient sample characteristics and in vitro gefitinib EC50
Patient . | Diagnosis . | EC50, μM . | Cytogenetic findings . |
|---|---|---|---|
| 1 | M3-AML | 1.84 | 47, XX, +8, t(15;17) (q22;q21) |
| 2 | M5-AML | 1.00 | 45, XY, −7 |
| 3 | M4-AML | 3.94 | 46, XX, ? t(3;7) (q25-26; q35-36) [7]/46, XX [13]/46, XY [1] |
| 4 | M1-AML | 8.11 | 46, XY, der(6) ins(6;?) (q23;?) t(6;7) (q25;p13-14), der(7) add(7) (p13-14) del(7) 9 (q22q34), del(11) (q2?3), del(12) (q13q24) .ish der(6) (MLL+), del(11) (MLL−) |
| 5 | M1-AML | 1.21 | 45, XY, −7 [6]/46, XY [14] |
| 6 | M5-AML | 2.63 | 46, XX |
| 7 | M4-AML | 1.39 | 46, XY |
| 8 | M1-AML | 5.89 | 47, XY, +8 |
Patient . | Diagnosis . | EC50, μM . | Cytogenetic findings . |
|---|---|---|---|
| 1 | M3-AML | 1.84 | 47, XX, +8, t(15;17) (q22;q21) |
| 2 | M5-AML | 1.00 | 45, XY, −7 |
| 3 | M4-AML | 3.94 | 46, XX, ? t(3;7) (q25-26; q35-36) [7]/46, XX [13]/46, XY [1] |
| 4 | M1-AML | 8.11 | 46, XY, der(6) ins(6;?) (q23;?) t(6;7) (q25;p13-14), der(7) add(7) (p13-14) del(7) 9 (q22q34), del(11) (q2?3), del(12) (q13q24) .ish der(6) (MLL+), del(11) (MLL−) |
| 5 | M1-AML | 1.21 | 45, XY, −7 [6]/46, XY [14] |
| 6 | M5-AML | 2.63 | 46, XX |
| 7 | M4-AML | 1.39 | 46, XY |
| 8 | M1-AML | 5.89 | 47, XY, +8 |
Primary patient leukemia blasts were collected by ficoll separation from bone marrow aspirate or peripheral blood. FAB subclass and cytogenetic findings are reported. The gefitinib concentration at which cell viability is 50% of DMSO-treated control cells (EC50) was determined at 6 days by an ATP-based assay performed in 4 replicates.